Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 343-351 , April 2008

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA–MORAb-003

  • Peter M. Smith-Jones

      Affiliations

    • Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 646 888 2212; fax: +1 646 422 0408.
    • ,
  • Neeta Pandit-Taskar

      Affiliations

    • Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    • ,
  • Wei Cao

      Affiliations

    • Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    • ,
  • Joseph O'Donoghue

      Affiliations

    • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    • ,
  • Martin D. Philips

      Affiliations

    • Morphotek Inc., Exton, PA 19341, USA
    • ,
  • Jorge Carrasquillo

      Affiliations

    • Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    • ,
  • Jason A. Konner

      Affiliations

    • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    • ,
  • Lloyd J. Old

      Affiliations

    • Ludwig Institute for Cancer Research, New York, NY 10158, USA
    • ,
  • Steven M. Larson

      Affiliations

    • Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA

Received 9 July 2007 ,Revised 11 December 2007 ,Accepted 23 December 2007.

References 

  1. Rettig WJ, Cordon-Cardo C, Koulos JP, Lewis JL, Oettgen HF, Old LJ. Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. Int J Cancer. 1985;35(4):469–475
  2. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?. Int J Cancer. 2006;119(2):243–250
  3. Lu Y, Low PS. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J Control Release. 2003;91(1–2):17–29
  4. van Zanten-Przybysz I, Molthoff C, Gebbinck JK, et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol. 2002;128(9):484–492
  5. Molthoff CF, Buist MR, Kenemans P, Pinedo HM, Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med. 1992;33(11):2000–2005
  6. Gadina M, Canevari S, Ripamonti M, Mariani M, Colnaghi MI. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma mAb MOv18. Int J Rad Appl Instrum B. 1991;18(4):403–408
  7. Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol. 1999;38(3):323–328
  8. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res. 2003;9(10 Pt 2):3914S–3921S
  9. Coliva A, Zacchetti A, Luison E, et al. 90Y labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005;54(12):1200–1213
  10. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6–13
  11. Markwell MA, Fox CF. Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3alpha,6alpha-diphenylglycoluril. Biochemistry. 1978;17(22):4807–4817
  12. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60(18):5237–5243
  13. Lindmo T, Bunn PA. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol. 1986;121:678–691
  14. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1989;30(5):672–682
  15. Meares CF, Moi MK, Diril H, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl. 1990;10:21–26
  16. Moi MK, DeNardo SJ, Meares CF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 1990;50(3 Suppl):789s–793s
  17. Camera L, Kinuya S, Garmestani K, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994;35(5):882–889
  18. Lewis MR, Raubitschek A, Shively JE. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug Chem. 1994;5(6):565–576
  19. Stein R, Chen S, Haim S, Goldenberg DM. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer. 1997;80(12 Suppl):2636–2641
  20. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269(5):3198–3204
  21. Miotti S, Facheris P, Tomassetti A, et al. Growth of ovarian-carcinoma cell lines at physiological folate concentration: effect on folate-binding protein expression in vitro and in vivo. Int J Cancer. 1995;63(3):395–401
  22. Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol. 2004;66(6):1406–1414

☆ P.M.S.-J. and N.P.T. contributed equally to this work.

PII: S0969-8051(08)00006-1

doi: 10.1016/j.nucmedbio.2007.12.008

Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 343-351 , April 2008

Article Tools

* Image Usage & Resolution